Description of the clinical case of the use of the apremilast in a patient with an oncological history
- Autores: Khotko A.A1, Pomazanova M.Y.1
-
Afiliações:
- Clinical Dermatovenerologic Dispensary, Krasnodar
- Edição: Volume 27, Nº 8 (2020)
- Páginas: 97-101
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312772
- DOI: https://doi.org/10.18565/pharmateca.2020.8.97-100
- ID: 312772
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Background. Apremilast is the first representative of low-molecular targeted disease-modifying anti-inflammatory drugs for the treatment of psoriasis and psoriatic arthritis (PsA). Apremilast is selective phosphodiesterase-4 (PDE-4) inhibitor. Obviously, in the future, apremilast will occupy an important place in the treatment of psoriasis and PsA due to its oral form, proven effectiveness in relation to various forms of psoriasis and a favorable safety profile. Description of the clinical case. An example of the successful use of amremilast therapy in the treatment of a patient with vulgar psoriasis, PsA and an oncological history (breast cancer) is presented. A fast and stable normalization of PASI parameters with the disappearance of skin elements was achieved. The treatment was well tolerated; no adverse events were observed during therapy. Conclusion. It can be concluded that the use of the PDE-4 inhibitor apremilast allows to control psoriasis and improve the quality of life of patients, including with concomitant pathology.
Palavras-chave
Texto integral
Sobre autores
A. Khotko
Clinical Dermatovenerologic Dispensary, Krasnodar
Email: alkes@inbox.ru
Cand. Sci. (Med.), Associate Professor, Deputy-Chief Physician of the Clinical
M. Pomazanova
Clinical Dermatovenerologic Dispensary, Krasnodar
Bibliografia
- Потекаев Н.Н., Круглова Л.С. Псориатическая болезнь. М., 2014. 264 с
- Круглова Л.С., Львов А.Н. Ранняя диагностика псориатического артрита и возможности контроля над заболевание (обзор литературы). Медицинский Алфавит. Дерматология. 2019;2(26):44-50.
- Gladman D.D. Psoriatic arthritis: epidemiology. Psoriasis and Psoriatic arthritis. 2005. Р. 57-66. (In Russ.)].
- Бунчук Н.В. Псориатический артрит. Ревматология: национальное руководство. М.: ГЭОТАР-МЕДИА, 2008. С. 355-66.
- Ritchlin C.T. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol. 2005;17:406-12.
- Barton J., Ritchlin C.T. Psoriatic arthritis: immunopathogenesis. Psoriasis and Psoriatic arthritis. 2005. Р. 37-45.
- Круглова Л.С., Моисеев С.В. Блокада интерлейкина-17 - новые горизонты эффективности и безопасности в лечении псориаза. Клиническая фармакология и терапия. 2017;26(2):5-
- Коротаева Т.В. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология. 2014;52(6):650-59.
- Национальное руководство по ревматологии. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010. 320 с.
- Gossec L., Smolen J.S., Ramiro S., et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499-510. doi: 10.1136/annrheumdis-2015-208337.
- Coates L.C., Kavanaugh A., Mease PJ., et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis: treatment recommendations for psoriatic arthritis 2015. Arthritis Rheumatol. 2016;68:1060-71. doi: 10.1002/art.39573.
- Keating G.M. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017;77(4):459-72. doi: 10.1007/s40265-017-0709-1.
- Abdulrahim H., Thistleton S., Adebajo A.O., et al. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2015;16(7):1099108. doi: 10.1517/14656566.2015.1034107.
- Haber S.L., Hamilton S., Bank M., et al. Apremilast: a novel drug for treatment of psoriasis and psoriatic arthritis. Ann Pharmacother. 2016;50(4):282-90. doi: 10.1177/1060028015627467.
- Gossec L., Smolen J.S., Ramiro S., et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499-510. doi: 10.1136/annrheumdis-2015-208337.
- Coates L.C., Kavanaugh A., Mease PJ., et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis: treatment recommendations for psoriatic arthritis 2015. Arthritis Rheumatol. 2016;68:1060-71. doi: 10.1002/art.39573.
- Кубанов А.А. Резолюция Совета российских экспертов: «Апремиласт, ингибитор фосфодиэсте-разы 4, как представитель нового класса малых молекул: место в лечении среднетяжелого, тяжелого псориаза и псориатического артрита». Современная ревматология. 2017;11(1):87 9